Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-03-20

FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)

View source ↗

Summary

The FDA approved a supplemental application for Ledipasvir and Sofosbuvir (Harvoni) submitted by Asegua Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HARVONI (Ledipasvir and Sofosbuvir)

Snippet

SUPPL AP for LEDIPASVIR AND SOFOSBUVIR (LEDIPASVIR AND SOFOSBUVIR)